On Tuesday, Piper Sandler reiterated its Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) with a steady price target of $7.00. The firm's stance remains bullish on TSHA shares following the release of competitor data.
The analysis suggests that Taysha's TSHA-102 for Rett syndrome shows comparable efficacy to NGN-401, a similar treatment by a competitor not covered by Piper Sandler. The competitor's high-dose patient experienced a serious adverse event (SAE) related to their AAV gene therapy, which has not been observed with TSHA-102.
The firm's confidence in Taysha Gene Therapies has been bolstered by recent events in the competitive landscape. Despite TSHA shares declining approximately 23% since the announcement of the efficacy data presentation date for NGN-401, Piper Sandler anticipates a recovery.
The concern had been that NGN-401 would outperform TSHA-102, but with the reported SAE and comparable efficacy, the firm expects investor sentiment to shift positively towards TSHA.
Piper Sandler's analysis highlights that no serious adverse events related to AAV gene therapy have been reported with TSHA-102, which could be a significant advantage over the competitor's gene therapy. The firm indicates that this safety profile, coupled with the upcoming high-dose data for TSHA-102 expected in the first half of 2025, should encourage investor confidence and buying activity.
The firm's note suggests that the recent drop in Taysha's stock price was largely driven by investor concerns over potential competition from NGN-401. However, with the latest data from the competitor not demonstrating a significant differentiation in efficacy and the occurrence of an SAE, the outlook for Taysha appears more favorable.
In conclusion, Piper Sandler maintains its $7 price target for Taysha Gene Therapies and encourages investors to buy shares on the open market. The firm expects that the shares will recover as investor focus shifts to the anticipated high-dose data for TSHA-102 in the first half of 2025.
In other recent news, Taysha Gene Therapies has made significant advancements in its TSHA-102 gene therapy program for Rett Syndrome.
The company has reported positive safety and efficacy data from its Phase 1/2 trials' low-dose cohort and has initiated the high-dose cohort while expanding the pediatric trial into Canada. Despite a net loss of $20.9 million for the quarter, Taysha maintains a stable financial position with $172.7 million in cash, extended by a public follow-on offering into the fourth quarter of 2026.
In addition, several analyst firms have recently provided their take on Taysha's prospects. Baird reiterated an Outperform rating with a $7.00 price target, BMO Capital Markets maintained an Outperform rating with a $5.00 price target, and Canaccord Genuity maintained a Buy rating while adjusting its price target to $6.00.
These affirmations and adjustments reflect the analysts' views on the company's strategic advancements and financial stability.
These are recent developments in Taysha Gene Therapies' ongoing efforts to advance their TSHA-102 gene therapy candidate for Rett Syndrome. The company plans to share safety and efficacy data from high-dose cohorts and updates on low-dose cohorts in 2025.
Taysha aims to develop a transformative therapy for Rett Syndrome, a condition with no approved disease-modifying treatments, and is anticipating discussions with the FDA to facilitate updates.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Taysha Gene Therapies' financial position and market performance. Despite the company's recent stock price decline, InvestingPro Tips highlight that TSHA has seen a significant return over the last week, with a 28.35% price total return. This aligns with Piper Sandler's expectation of a potential recovery in investor sentiment.
However, it's important to note that TSHA is quickly burning through cash and is not profitable over the last twelve months. The company's operating income margin stands at -598.62%, reflecting the significant costs associated with developing gene therapies. On a positive note, TSHA holds more cash than debt on its balance sheet, which could provide some financial flexibility as it progresses towards its anticipated high-dose data release in 2025.
Investors should be aware that analysts anticipate a sales decline in the current year, with revenue growth (quarterly) at -53.57%. This underscores the importance of the upcoming TSHA-102 data in potentially driving future growth.
For those seeking a more comprehensive analysis, InvestingPro offers 9 additional tips for TSHA, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.